Instil Bio, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
Instil Bio, Inc. (TIL) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of -$948.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2026-03-27
- Instil Bio, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-12-31 was $164.00K.
- Instil Bio, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-09-30 was $167.00K.
- Instil Bio, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-06-30 was -$257.00K.
- Instil Bio, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-03-31 was $220.00K.
- Instil Bio, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2025 was -$948.00K.
- Instil Bio, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2024 was -$3.91M.
- Instil Bio, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2023 was -$3.38M.
- Instil Bio, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2022 was -$2.88M, a 1079.25% decline from fiscal 2021.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$948.00K 10-K · filed 2026-03-27 | |||
| 2024-12-31 | -$3.91M 10-K · filed 2026-03-27 | |||
| 2023-12-31 | -$3.38M 10-K · filed 2025-03-04 | |||
| 2022-12-31 | -$2.88M 10-K · filed 2024-03-21 | |||
| 2021-12-31 | $164.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $331.00K derived: sum of 2 quarters · filed 2023-03-31 | $74.00K derived: sum of 3 quarters · filed 2023-03-31 | $294.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$90.00K derived: sum of 2 quarters · filed 2021-11-15 | $130.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$257.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$37.00K 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $220.00K 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $928.00K 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |